Terns' Duchenne Drug Faces Competitive Doubts
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Terns' drug for Duchenne muscular dystrophy is now considered potentially less competitive than initially believed.
- Gilead is noted for its ongoing merger and acquisition streak within the biotech industry.
- A controversial class of drugs for Duchenne is a significant topic of discussion in the biotech news, adding context to Terns' drug's competitive landscape.
Why it matters: The competitive standing of Terns' Duchenne drug directly impacts patient access to new treatments and the company's market valuation.
Ask SkimNews
